1.
Union Med Can
; 115(7): 434-8, 1986 Jul.
Artigo
em Francês
| MEDLINE
| ID: mdl-3750566
2.
Union Med Can
; 115(7): 432-3, 1986 Jul.
Artigo
em Francês
| MEDLINE
| ID: mdl-3750565
3.
Union Med Can
; 115(7): 439-43, 1986 Jul.
Artigo
em Francês
| MEDLINE
| ID: mdl-3750567
4.
Union Med Can
; 115(7): 446-50, 1986 Jul.
Artigo
em Francês
| MEDLINE
| ID: mdl-2944265
5.
Can J Cardiol
; 1(2): 97-105, 1985 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-2864991
RESUMO
The institution of a "Cardioprophylactic" drug regimen after myocardial infarction should take into consideration the concept of high or low risk patients for secondary coronary events and the concept of a decremential mortality rate as time elapses after myocardial infarction. Thus, the efficacy of a particular drug in preventing secondary coronary events may vary with the time elapsed from infarction and thus with the underlying patho-physiologic mechanism. Furthermore, the administration of a possible effective or proven effective "Cardioprophylactic" drug or drug regimen at a specific time from infarction must take into account the balance between expected benefit and untoward side effects.